Top Dividend Stocks in Healthcare
We like Pfizer, Roche, Allergan, and Medtronic in this space.
Damien Conover: We are talking about dividends in the healthcare sector today. When we think about dividends within this sector, most of the companies that are going to be paying dividends are in the large-cap pharmaceutical or large-cap biotechnology space. Most of these dividends in their history have been very, very safe, and we think that's very likely to be the case going forward. These firms generate enormous amounts of cash flows and can really support strong dividend payouts.
A couple of names we want to highlight as far as stocks that we think are both undervalued and have strong dividends are, first within the pharmaceutical space, will be Pfizer. Pfizer is a name that has a nice growth potential, not a lot of patent losses, and is really set up well to pay out a continual stream of dividends. This is a firm that we think is undervalued and underappreciated with a very strong pipeline. That pipeline will really help the firm be able to generate that future cash flow that will be needed for the dividend.
Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.